U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H25NO.ClH
Molecular Weight 295.847
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EPERISONE HYDROCHLORIDE

SMILES

Cl.CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2

InChI

InChIKey=GTAXGNCCEYZRII-UHFFFAOYSA-N
InChI=1S/C17H25NO.ClH/c1-3-15-7-9-16(10-8-15)17(19)14(2)13-18-11-5-4-6-12-18;/h7-10,14H,3-6,11-13H2,1-2H3;1H

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/18836866

Eperisone is an antispasmodic drug approved in Japan for the treatment of of diseases characterized by muscle stiffness and pain. It is believed that eperisone exerts its effect through inhibition of sodium channels. The drug is still being marketed in Asia under the name Myonal (Square Pharmaceuticals).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
MYONAL

Approved Use

Improvement of myotonic conditions caused by Neck-shoulder-arm syndrome, scapulohumeral periarthritis and low back pain; Spastic paralysis caused by the following diseases: Cerebrovascular disorders, spastic spinal paralysis, cervical spondylosis, post-surgical sequelae (including cerebrospinal tumor), sequelae of trauma (spinal injury and head injury), amyotrophic lateral sclerosis, infantile cerebral palsy, spinocerebellar degeneration, spinal vascular disorders, subacute myelo-optico neuropathy (SMON) and other encephalomyelopathies.
Palliative
MYONAL

Approved Use

Improvement of myotonic conditions caused by Neck-shoulder-arm syndrome, scapulohumeral periarthritis and low back pain; Spastic paralysis caused by the following diseases: Cerebrovascular disorders, spastic spinal paralysis, cervical spondylosis, post-surgical sequelae (including cerebrospinal tumor), sequelae of trauma (spinal injury and head injury), amyotrophic lateral sclerosis, infantile cerebral palsy, spinocerebellar degeneration, spinal vascular disorders, subacute myelo-optico neuropathy (SMON) and other encephalomyelopathies.
Palliative
MYONAL

Approved Use

Improvement of myotonic conditions caused by Neck-shoulder-arm syndrome, scapulohumeral periarthritis and low back pain; Spastic paralysis caused by the following diseases: Cerebrovascular disorders, spastic spinal paralysis, cervical spondylosis, post-surgical sequelae (including cerebrospinal tumor), sequelae of trauma (spinal injury and head injury), amyotrophic lateral sclerosis, infantile cerebral palsy, spinocerebellar degeneration, spinal vascular disorders, subacute myelo-optico neuropathy (SMON) and other encephalomyelopathies.
Palliative
MYONAL

Approved Use

Improvement of myotonic conditions caused by Neck-shoulder-arm syndrome, scapulohumeral periarthritis and low back pain; Spastic paralysis caused by the following diseases: Cerebrovascular disorders, spastic spinal paralysis, cervical spondylosis, post-surgical sequelae (including cerebrospinal tumor), sequelae of trauma (spinal injury and head injury), amyotrophic lateral sclerosis, infantile cerebral palsy, spinocerebellar degeneration, spinal vascular disorders, subacute myelo-optico neuropathy (SMON) and other encephalomyelopathies.
PubMed

PubMed

TitleDatePubMed
Determination of eperisone in human plasma by liquid chromatography-ESI-tandem mass spectrometry.
2007 Sep
Efficacy and safety of eperisone in patients with low back pain: a double blind randomized study.
2008 Jul-Aug
Patents

Sample Use Guides

150 mg of eperisone hydrochloride daily in three divided doses after meals
Route of Administration: Oral
In Vitro Use Guide
Eperisone (25–200 uM) depressed the ventral root potential of isolated hemisected spinal cord of 6-day-old rats.
Name Type Language
EPERISONE HYDROCHLORIDE
MART.   MI   WHO-DD  
Common Name English
EPERISONE HYDROCHLORIDE [JAN]
Common Name English
1-(4-ETHYLPHENYL)-2-METHYL-3-(1-PIPERIDINYL)-1-PROPANONE HYDROCHLORIDE
Systematic Name English
Eperisone hydrochloride [WHO-DD]
Common Name English
MIONAL
Brand Name English
4'-ETHYL-2-METHYL-3-PIPERIDINOPROPIOPHENONE HYDROCHLORIDE
Systematic Name English
EPERISONE HYDROCHLORIDE [MI]
Common Name English
MYONAL
Brand Name English
EPERISONE HCL
Common Name English
EPERISONE HYDROCHLORIDE [MART.]
Common Name English
EMPP
Common Name English
E-646
Code English
Classification Tree Code System Code
NCI_THESAURUS C66880
Created by admin on Sat Dec 16 05:10:58 UTC 2023 , Edited by admin on Sat Dec 16 05:10:58 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID8047844
Created by admin on Sat Dec 16 05:10:58 UTC 2023 , Edited by admin on Sat Dec 16 05:10:58 UTC 2023
PRIMARY
PUBCHEM
123698
Created by admin on Sat Dec 16 05:10:58 UTC 2023 , Edited by admin on Sat Dec 16 05:10:58 UTC 2023
PRIMARY
SMS_ID
100000087244
Created by admin on Sat Dec 16 05:10:58 UTC 2023 , Edited by admin on Sat Dec 16 05:10:58 UTC 2023
PRIMARY
CAS
56839-43-1
Created by admin on Sat Dec 16 05:10:58 UTC 2023 , Edited by admin on Sat Dec 16 05:10:58 UTC 2023
PRIMARY
MERCK INDEX
m4931
Created by admin on Sat Dec 16 05:10:58 UTC 2023 , Edited by admin on Sat Dec 16 05:10:58 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL1902981
Created by admin on Sat Dec 16 05:10:58 UTC 2023 , Edited by admin on Sat Dec 16 05:10:58 UTC 2023
PRIMARY
FDA UNII
U38O8U7P6X
Created by admin on Sat Dec 16 05:10:58 UTC 2023 , Edited by admin on Sat Dec 16 05:10:58 UTC 2023
PRIMARY
NCI_THESAURUS
C83693
Created by admin on Sat Dec 16 05:10:58 UTC 2023 , Edited by admin on Sat Dec 16 05:10:58 UTC 2023
PRIMARY
DRUG BANK
DB08992
Created by admin on Sat Dec 16 05:10:58 UTC 2023 , Edited by admin on Sat Dec 16 05:10:58 UTC 2023
PRIMARY
EVMPD
SUB01900MIG
Created by admin on Sat Dec 16 05:10:58 UTC 2023 , Edited by admin on Sat Dec 16 05:10:58 UTC 2023
PRIMARY